Proteome changes in rat plasma in response to sibutramine

Proteomics

Volumn 11, Issue 7, 2011, Pages 1300-1312

  Choi, Jung Won ^a   Joo, Jeong In ^a   Kim, Dong Hyun ^a   Wang, Xia ^a   Oh, Tae Seok ^a   Choi, Duk Kwon ^a   Yun, Jong Won ^a  

^a Daegu University   (South Korea)

Author keywords

2 DE; Animal proteomics; Appetite regulation; Cardiovascular risk; Plasma proteome; Sibutramine

Indexed keywords

INSULIN; LEPTIN; PLASMA PROTEIN; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; FOOD INTAKE; IMMUNOBLOTTING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT;

ADIPOSE TISSUE; ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; BLOOD PROTEINS; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, LIQUID; CYCLOBUTANES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; INSULIN; LEPTIN; MALE; OBESITY; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; WEIGHT LOSS;

ANIMALIA; RATTUS;

EID: 79953066219     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000664     Document Type: Article

References (60)

1. Garaulet, M., Ordovas, J. M., Madrid, J. A., The chronobiology, etiology and pathophysiology of obesity. Int. J. Obes. 2010, 34, 1667-1683.
2. Coutinho, W., The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq. Bras. Endocrinol. Metabol. 2009, 53, 262-270.
3. James, W. P., Astrup, A., Finer, N., Hilsted, J. et al., Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356, 2119-2125.
4. Li, Z., Maglione, M., Tu, W., Mojica, W. et al., Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 2005, 142, 532-546.
5. Buckett, W. R., Thomas, P. C., Luscombe, G. P., The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog. Neuropsychopharmacol. Biol. Psychiatry 1988, 12, 575-584.
6. Le Feuvre, R. A., Aisenthal, L., Rothwell, N. J., Involvement of corticotrophin releasing factor (CRF) in the thermogenic and anorexic actions of serotonin (5-HT) and related compounds. Brain Res. 1991, 555, 245-250.
7. Wellman, P. J., Norepinephrine and the control of food intake. Nutrition 2000, 16, 837-842.
8. Halford, J. C., Wanninayake, S. C., Blundell, J. E., Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol. Biochem. Behav. 1998, 61, 159-168.
9. Connoley, I. P., Liu, Y. L., Frost, I., Reckless, I. P. et al., Thermogenic effects of sibutramine and its metabolites. Br. J. Pharmacol. 1999, 126, 1487-1495.
10. Day, C., Bailey, C. J., Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int. J. Obes. Relat. Metab. Disord. 1998, 22, 619-623.
11. Baranowska, B., Wolinska-Witort, E., Martynska, L., Chmielowska, M. et al., Sibutramine therapy in obese women - effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol. Lett. 2005, 26, 675-679.
12. Rodrigues, A. M., Radominski, R. B., Suplicy Hde, L., De Almeida, S. M. et al., The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J. Clin. Endocrinol. Metab. 2002, 87, 1621-1626.
13. Bray, G. A., Greenway, F. L., Pharmacological treatment of the overweight patient. Pharmacol. Rev. 2007, 59, 151-184.
14. Kim, S. H., Lee, Y. M., Jee, S. H., Nam, C. M., Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes. Res. 2003, 11, 1116-1123.
15. FDA. Early communication about an ongoing safety review of Meridia (sibutramine hydrochloride). 2009.
16. FDA. Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review. 2010.
17. Kim, S. W., Hwang, H. J., Baek, Y. M., Lee, S. H. et al., Proteomic and transcriptomic analysis for streptozotocin-induced diabetic rat pancreas in response to fungal polysaccharide treatments. Proteomics 2008, 8, 2344-2361.
18. de Graaf, C., Blom, W. A., Smeets, P. A., Stafleu, A., Hendriks, H. F., Biomarkers of satiation and satiety. Am. J. Clin. Nutr. 2004, 79, 946-961.
19. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
20. Mooradian, A. D., Haas, M. J., Wehmeier, K. R., Wong, N. C., Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring) 2008, 16, 1152-1160.
21. Jong, M. C., Voshol, P. J., Muurling, M., Dahlmans, V. E. et al., Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 2001, 50, 2779-2785.
22. Verges, B., Guerci, B., Durlach, V., Galland-Jos, C. et al., Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects. J. Lipid Res. 2001, 42, 2021-2029.
23. Tso, P., Liu, M., Kalogeris, T. J., Thomson, A. B., The role of apolipoprotein A-IV in the regulation of food intake. Annu. Rev. Nutr. 2001, 21, 231-254.
24. Chan, D. C., Nguyen, M. N., Watts, G. F., Barrett, P. H., Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J. Clin. Endocrinol. Metab. 2008, 93, 557-564.
25. Gao, J., Katagiri, H., Ishigaki, Y., Yamada, T. et al., Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007, 56, 24-33.
26. Shen, L., Tso, P., Woods, S. C., Clegg, D. J. et al., Brain apolipoprotein E: an important regulator of food intake in rats. Diabetes 2008, 57, 2092-2098.
27. Xu, N., Nilsson-Ehle, P., Ahren, B., Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J. Nutr. Biochem. 2004, 15, 579-582.
28. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., Dawber, T. R., High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 1977, 62, 707-714.
29. Moore, R. E., Navab, M., Millar, J. S., Zimetti, F. et al., Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 2005, 97, 763-771.
30. Skinner, J. S., Farrer, M., Albers, C. J., Neil, H. A., Adams, P. C., High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery. Heart 1999, 81, 488-494.
31. Cohen, R. D., Castellani, L. W., Qiao, J. H., Van Lenten, B. J. et al., Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J. Clin. Invest. 1997, 99, 1906-1916.
32. Onat, A., Hergenc, G., Sansoy, V., Fobker, M. et al., Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003, 168, 81-89.
33. Kang, J. H., Logroscino, G., De Vivo, I., Hunter, D., Grodstein, F., Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol. Aging 2005, 26, 475-484.
34. Kloting, N., Graham, T. E., Berndt, J., Kralisch, S. et al., Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007, 6, 79-87.
35. Lau, D. C., Dhillon, B., Yan, H., Szmitko, P. E., Verma, S., Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H2031-H2041.
36. Visser, M., Bouter, L. M., McQuillan, G. M., Wener, M. H., Harris, T. B., Elevated C-reactive protein levels in overweight and obese adults. J. Am. Med. Assoc. 1999, 282, 2131-2135.
37. Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Gallimore, J. R. et al., Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440, 1217-1221.
38. Ajjan, R., Grant, P. J., Futers, T. S., Brown, J. M. et al., Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb. Haemost. 2005, 94, 1048-1053.
39. Muscari, A., Bozzoli, C., Massarelli, G., Puddu, G. M. et al., Complement components and fibrinogen: correlations and association with previous myocardial infarction. Cardiology 1995, 86, 232-237.
40. Kim, C. H., Park, J. Y., Kim, J. Y., Choi, C. S. et al., Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a population-based study. Metabolism 2002, 51, 838-842.
41. Ebana, Y., Ozaki, K., Inoue, K., Sato, H. et al., A functional SNP in ITIH3 is associated with susceptibility to myocardial infarction. J. Hum. Genet. 2007, 52, 220-229.
42. Kashyap, R. S., Nayak, A. R., Deshpande, P. S., Kabra, D. et al., Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin. Chim. Acta 2009, 402, 160-163.
43. Stefan, N., Fritsche, A., Weikert, C., Boeing, H. et al., Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008, 57, 2762-2767.
44. Taes, Y. E., Goemaere, S., Huang, G., Van Pottelbergh, I. et al., Vitamin D binding protein, bone status and body composition in community-dwelling elderly men. Bone 2006, 38, 701-707.
45. Gil, G., Esser, V., Cholesterol-mediated suppression of alpha 1-inhibitor III, a plasma alpha-macroglobulin family protein. J. Biol. Chem. 1991, 266, 20512-20518.
46. Salas-Salvado, J., Bullo, M., Garcia-Lorda, P., Figueredo, R. et al., Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss. Int. J. Obes. 2006, 30, 1714-1720.
47. Shaper, A. G., Wannamethee, S. G., Whincup, P. H., Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J. Clin. Epidemiol. 2004, 57, 195-202.
48. Lee, Y. S., Kim, A. Y., Choi, J. W., Kim, M. et al., Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol. Endocrinol. 2008, 22, 2176-2189.
49. Gong, F. Y., Zhang, S. J., Deng, J. Y., Zhu, H. J. et al., Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int. J. Obes. 2009, 33, 1023-1030.
50. Degawa-Yamauchi, M., Bovenkerk, J. E., Juliar, B. E., Watson, W. et al., Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 2003, 88, 5452-5455.
51. Ukkola, O., Santaniemi, M., Adiponectin: a link between excess adiposity and associated comorbidities? J. Mol. Med. 2002, 80, 696-702.
52. Matsuzawa, Y., Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3, 35-42.
53. Weikert, C., Westphal, S., Berger, K., Dierkes, J. et al., Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J. Clin. Endocrinol. Metab. 2008, 93, 2647-2653.
54. Mallamaci, F., Zoccali, C., Cuzzola, F., Tripepi, G. et al., Adiponectin in essential hypertension. J. Nephrol. 2002, 15, 507-511.
55. Warnberg, J., Nova, E., Moreno, L. A., Romeo, J. et al., Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am. J. Clin. Nutr. 2006, 84, 505-512.
56. Cavusoglu, E., Eng, C., Chopra, V., Ruwende, C. et al., Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography. Am. J. Cardiol. 2007, 100, 164-168.
57. Moreno, L. A., Sarria, A., Lazaro, A., Bueno, M., Larrad, L., Serum C4 concentration and risk of atherosclerosis. Biometric J. 1994, 309, 1087.
58. Cignarelli, M., DePergola, G., Picca, G., Sciaraffia, M. et al., Relationship of obesity and body fat distribution with ceruloplasmin serum levels. Int. J. Obes. Relat. Metab. Disord. 1996, 20, 809-813.
59. Martinez Diaz, F., Rodriguez-Morlensin, M., Perez-Carceles, M. D., Noguera, J. et al., Biochemical analysis and immunohistochemical determination of cardiac troponin for the postmortem diagnosis of myocardial damage. Histol. Histopathol. 2005, 20, 475-481.
60. Brinkmann, B., Sepulchre, M. A., Fechner, G., The application of selected histochemical and immunohistochemical markers and procedures to the diagnosis of early myocardial damage. Int. J. Legal Med. 1993, 106, 135-141.